Business Context and Reporting Period
This Form 8-K Current Report was filed by Pacific Biosciences of California, Inc. on October 14, 2020. The filing discloses corporate governance actions taken by the Board of Directors regarding the appointment and compensation of the Chief Executive Officer.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation terms.
- Base Salary: $650,000 annually.
- Target Bonus: 100% of base salary ($650,000), subject to performance goals.
- Relocation Reimbursement: Up to $250,000.
- Stock Option Grant: 1,500,000 shares at an exercise price of $7.52 per share.
- Restricted Stock Unit (RSU) Grant: 750,000 shares.
Material Changes
On October 14, 2020, the Board appointed Christian O. Henry as President in addition to his existing role as Chief Executive Officer. This appointment was accompanied by the execution of a new Employment Agreement and a Change in Control and Severance Agreement, effective as of September 14, 2020.
Guidance, Outlook, and Risks
The filing contains no financial guidance or market outlook. Key terms regarding risk and contingencies include:
- Severance Terms: In the event of termination without cause or resignation for good reason, Mr. Henry is entitled to 18 months of base salary, 18 months of COBRA coverage, and accelerated vesting of equity awards (6 months of service-based vesting).
- Change in Control: If termination occurs within 12 months of a change in control, 100% of unvested equity awards accelerate, and performance goals are deemed achieved at 100% of target.
- Conditions: Severance benefits are contingent upon Mr. Henry signing and not revoking a separation agreement and release of claims.
Investor Verification Checklist
- Verify the full text of the Employment Agreement and Severance Agreement in the upcoming Form 10-Q for the quarter ended September 30, 2020.
- Confirm the specific performance goals established by the Board for the target bonus.
- Review the vesting schedules for the 1,500,000 stock options and 750,000 RSUs granted on September 15, 2020.
- Check for any outstanding equity awards previously granted to Mr. Henry in his capacity as a Board member.